Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients
OBJECTIVES:Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects...
Gespeichert in:
| Veröffentlicht in: | Critical care medicine 2019-07, Vol.47 (7), p.918-925 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 925 |
|---|---|
| container_issue | 7 |
| container_start_page | 918 |
| container_title | Critical care medicine |
| container_volume | 47 |
| creator | Schlosser, Kenny Wang, Jia-Pey dos Santos, Claudia Walley, Keith R. Marshall, John Fergusson, Dean A. Winston, Brent W. Granton, John Watpool, Irene Stewart, Duncan J. McIntyre, Lauralyn A. Mei, Shirley H. J. |
| description | OBJECTIVES:Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects of mesenchymal stem/stromal cell treatment, as no previous study has conducted a comprehensive analysis of circulating cytokine levels in critically ill patients treated with mesenchymal stem/stromal cells.
DESIGN:Phase 1 dose-escalation trial.
PATIENTS:The interventional cohort (n = 9) of septic shock patients received a single dose of 0.3, 1.0, or 3.0 million mesenchymal stem/stromal cells/kg body weight (n = 3 per dose). The observational cohort received no mesenchymal stem/stromal cells (n = 21).
INTERVENTIONS:Allogeneic bone marrow-derived mesenchymal stem/stromal cells.
MEASUREMENTS AND MAIN RESULTS:Serial plasma samples were collected at study baseline prior to mesenchymal stem/stromal cell infusion (0 hr), 1 hour, 4 hours, 12 hours, 24 hours, and 72 hours after mesenchymal stem/stromal cell infusion/trial enrollment. Forty-nine analytes comprised mostly of cytokines along with several biomarkers were measured. We detected no significant elevations in a broad range of pro-inflammatory cytokines and biomarkers between the interventional and observational cohorts. Stratification of the interventional cohort by mesenchymal stem/stromal cell dose further revealed patient-specific and dose-dependent perturbations in cytokines, including an early but transient dampening of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mesenchymal stem/stromal cell treatment may alter innate immune responses and underlying sepsis biology.
CONCLUSIONS:A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials. |
| doi_str_mv | 10.1097/CCM.0000000000003657 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6629173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179536814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5537-4b15f2cddd3914ef43b2dabc4552a69ab09ec7c83443f75efcf4f4e5b26b739d3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhDRDykUuKHdvx-oKE0qUgbUWlLWfLccYkrBMvsbdVHoG3rpctVeEAvow88__fWP4Rek3JGSVKvqvryzPy6LBKyCdoQQUjBSkVe4oWhChSMK7YCXoR43dCKBeSPUcnjMiSCLZcoJ8r58CmiIPDlxBhtN08GI83CQZcg_f4egKTBhgTDiPezDEPeovrOYVtPwJeww34iPsRG3zVmQiY4vOQyypa403qDy7jIM2Z1GdyXrSBXcqMTRfsFl9lTabHl-iZMz7Cq_t6ir5-XF3Xn4r1l4vP9Yd1YYVgsuANFa60bdsyRTk4zpqyNY3lQpSmUqYhCqy0S8Y5c1KAs447DqIpq0Yy1bJT9P7I3e2bAVqbd0_G693UD2aadTC9_nMy9p3-Fm50VZWKSpYBb-8BU_ixh5j00Eebv8qMEPZRl1Qqwaol5VnKj1I7hRgncA9rKNGHFHVOUf-dYra9efzEB9Pv2LJgeRTcBp9gilu_v4VJd2B86v7H5v-w_pKVvCpKQhWR-VYcWoLdAejYuuo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179536814</pqid></control><display><type>article</type><title>Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Schlosser, Kenny ; Wang, Jia-Pey ; dos Santos, Claudia ; Walley, Keith R. ; Marshall, John ; Fergusson, Dean A. ; Winston, Brent W. ; Granton, John ; Watpool, Irene ; Stewart, Duncan J. ; McIntyre, Lauralyn A. ; Mei, Shirley H. J.</creator><creatorcontrib>Schlosser, Kenny ; Wang, Jia-Pey ; dos Santos, Claudia ; Walley, Keith R. ; Marshall, John ; Fergusson, Dean A. ; Winston, Brent W. ; Granton, John ; Watpool, Irene ; Stewart, Duncan J. ; McIntyre, Lauralyn A. ; Mei, Shirley H. J. ; Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group ; on behalf of the Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</creatorcontrib><description>OBJECTIVES:Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects of mesenchymal stem/stromal cell treatment, as no previous study has conducted a comprehensive analysis of circulating cytokine levels in critically ill patients treated with mesenchymal stem/stromal cells.
DESIGN:Phase 1 dose-escalation trial.
PATIENTS:The interventional cohort (n = 9) of septic shock patients received a single dose of 0.3, 1.0, or 3.0 million mesenchymal stem/stromal cells/kg body weight (n = 3 per dose). The observational cohort received no mesenchymal stem/stromal cells (n = 21).
INTERVENTIONS:Allogeneic bone marrow-derived mesenchymal stem/stromal cells.
MEASUREMENTS AND MAIN RESULTS:Serial plasma samples were collected at study baseline prior to mesenchymal stem/stromal cell infusion (0 hr), 1 hour, 4 hours, 12 hours, 24 hours, and 72 hours after mesenchymal stem/stromal cell infusion/trial enrollment. Forty-nine analytes comprised mostly of cytokines along with several biomarkers were measured. We detected no significant elevations in a broad range of pro-inflammatory cytokines and biomarkers between the interventional and observational cohorts. Stratification of the interventional cohort by mesenchymal stem/stromal cell dose further revealed patient-specific and dose-dependent perturbations in cytokines, including an early but transient dampening of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mesenchymal stem/stromal cell treatment may alter innate immune responses and underlying sepsis biology.
CONCLUSIONS:A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/CCM.0000000000003657</identifier><identifier>PMID: 30720538</identifier><language>eng</language><publisher>United States: The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc</publisher><subject>Adult ; Biomarkers ; Clinical Investigations ; Cytokines - biosynthesis ; Dose-Response Relationship, Drug ; Female ; Humans ; Inflammation Mediators - metabolism ; Male ; Mesenchymal Stem Cell Transplantation - adverse effects ; Mesenchymal Stem Cell Transplantation - methods ; Middle Aged ; Severity of Illness Index ; Shock, Septic - metabolism ; Shock, Septic - therapy</subject><ispartof>Critical care medicine, 2019-07, Vol.47 (7), p.918-925</ispartof><rights>The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.</rights><rights>Copyright © by 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.</rights><rights>Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5537-4b15f2cddd3914ef43b2dabc4552a69ab09ec7c83443f75efcf4f4e5b26b739d3</citedby><cites>FETCH-LOGICAL-c5537-4b15f2cddd3914ef43b2dabc4552a69ab09ec7c83443f75efcf4f4e5b26b739d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30720538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schlosser, Kenny</creatorcontrib><creatorcontrib>Wang, Jia-Pey</creatorcontrib><creatorcontrib>dos Santos, Claudia</creatorcontrib><creatorcontrib>Walley, Keith R.</creatorcontrib><creatorcontrib>Marshall, John</creatorcontrib><creatorcontrib>Fergusson, Dean A.</creatorcontrib><creatorcontrib>Winston, Brent W.</creatorcontrib><creatorcontrib>Granton, John</creatorcontrib><creatorcontrib>Watpool, Irene</creatorcontrib><creatorcontrib>Stewart, Duncan J.</creatorcontrib><creatorcontrib>McIntyre, Lauralyn A.</creatorcontrib><creatorcontrib>Mei, Shirley H. J.</creatorcontrib><creatorcontrib>Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</creatorcontrib><creatorcontrib>on behalf of the Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</creatorcontrib><title>Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVES:Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects of mesenchymal stem/stromal cell treatment, as no previous study has conducted a comprehensive analysis of circulating cytokine levels in critically ill patients treated with mesenchymal stem/stromal cells.
DESIGN:Phase 1 dose-escalation trial.
PATIENTS:The interventional cohort (n = 9) of septic shock patients received a single dose of 0.3, 1.0, or 3.0 million mesenchymal stem/stromal cells/kg body weight (n = 3 per dose). The observational cohort received no mesenchymal stem/stromal cells (n = 21).
INTERVENTIONS:Allogeneic bone marrow-derived mesenchymal stem/stromal cells.
MEASUREMENTS AND MAIN RESULTS:Serial plasma samples were collected at study baseline prior to mesenchymal stem/stromal cell infusion (0 hr), 1 hour, 4 hours, 12 hours, 24 hours, and 72 hours after mesenchymal stem/stromal cell infusion/trial enrollment. Forty-nine analytes comprised mostly of cytokines along with several biomarkers were measured. We detected no significant elevations in a broad range of pro-inflammatory cytokines and biomarkers between the interventional and observational cohorts. Stratification of the interventional cohort by mesenchymal stem/stromal cell dose further revealed patient-specific and dose-dependent perturbations in cytokines, including an early but transient dampening of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mesenchymal stem/stromal cell treatment may alter innate immune responses and underlying sepsis biology.
CONCLUSIONS:A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials.</description><subject>Adult</subject><subject>Biomarkers</subject><subject>Clinical Investigations</subject><subject>Cytokines - biosynthesis</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation Mediators - metabolism</subject><subject>Male</subject><subject>Mesenchymal Stem Cell Transplantation - adverse effects</subject><subject>Mesenchymal Stem Cell Transplantation - methods</subject><subject>Middle Aged</subject><subject>Severity of Illness Index</subject><subject>Shock, Septic - metabolism</subject><subject>Shock, Septic - therapy</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EokvhDRDykUuKHdvx-oKE0qUgbUWlLWfLccYkrBMvsbdVHoG3rpctVeEAvow88__fWP4Rek3JGSVKvqvryzPy6LBKyCdoQQUjBSkVe4oWhChSMK7YCXoR43dCKBeSPUcnjMiSCLZcoJ8r58CmiIPDlxBhtN08GI83CQZcg_f4egKTBhgTDiPezDEPeovrOYVtPwJeww34iPsRG3zVmQiY4vOQyypa403qDy7jIM2Z1GdyXrSBXcqMTRfsFl9lTabHl-iZMz7Cq_t6ir5-XF3Xn4r1l4vP9Yd1YYVgsuANFa60bdsyRTk4zpqyNY3lQpSmUqYhCqy0S8Y5c1KAs447DqIpq0Yy1bJT9P7I3e2bAVqbd0_G693UD2aadTC9_nMy9p3-Fm50VZWKSpYBb-8BU_ixh5j00Eebv8qMEPZRl1Qqwaol5VnKj1I7hRgncA9rKNGHFHVOUf-dYra9efzEB9Pv2LJgeRTcBp9gilu_v4VJd2B86v7H5v-w_pKVvCpKQhWR-VYcWoLdAejYuuo</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Schlosser, Kenny</creator><creator>Wang, Jia-Pey</creator><creator>dos Santos, Claudia</creator><creator>Walley, Keith R.</creator><creator>Marshall, John</creator><creator>Fergusson, Dean A.</creator><creator>Winston, Brent W.</creator><creator>Granton, John</creator><creator>Watpool, Irene</creator><creator>Stewart, Duncan J.</creator><creator>McIntyre, Lauralyn A.</creator><creator>Mei, Shirley H. J.</creator><general>The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc</general><general>Copyright by by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc</general><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201907</creationdate><title>Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients</title><author>Schlosser, Kenny ; Wang, Jia-Pey ; dos Santos, Claudia ; Walley, Keith R. ; Marshall, John ; Fergusson, Dean A. ; Winston, Brent W. ; Granton, John ; Watpool, Irene ; Stewart, Duncan J. ; McIntyre, Lauralyn A. ; Mei, Shirley H. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5537-4b15f2cddd3914ef43b2dabc4552a69ab09ec7c83443f75efcf4f4e5b26b739d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Biomarkers</topic><topic>Clinical Investigations</topic><topic>Cytokines - biosynthesis</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation Mediators - metabolism</topic><topic>Male</topic><topic>Mesenchymal Stem Cell Transplantation - adverse effects</topic><topic>Mesenchymal Stem Cell Transplantation - methods</topic><topic>Middle Aged</topic><topic>Severity of Illness Index</topic><topic>Shock, Septic - metabolism</topic><topic>Shock, Septic - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlosser, Kenny</creatorcontrib><creatorcontrib>Wang, Jia-Pey</creatorcontrib><creatorcontrib>dos Santos, Claudia</creatorcontrib><creatorcontrib>Walley, Keith R.</creatorcontrib><creatorcontrib>Marshall, John</creatorcontrib><creatorcontrib>Fergusson, Dean A.</creatorcontrib><creatorcontrib>Winston, Brent W.</creatorcontrib><creatorcontrib>Granton, John</creatorcontrib><creatorcontrib>Watpool, Irene</creatorcontrib><creatorcontrib>Stewart, Duncan J.</creatorcontrib><creatorcontrib>McIntyre, Lauralyn A.</creatorcontrib><creatorcontrib>Mei, Shirley H. J.</creatorcontrib><creatorcontrib>Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</creatorcontrib><creatorcontrib>on behalf of the Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlosser, Kenny</au><au>Wang, Jia-Pey</au><au>dos Santos, Claudia</au><au>Walley, Keith R.</au><au>Marshall, John</au><au>Fergusson, Dean A.</au><au>Winston, Brent W.</au><au>Granton, John</au><au>Watpool, Irene</au><au>Stewart, Duncan J.</au><au>McIntyre, Lauralyn A.</au><au>Mei, Shirley H. J.</au><aucorp>Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</aucorp><aucorp>on behalf of the Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2019-07</date><risdate>2019</risdate><volume>47</volume><issue>7</issue><spage>918</spage><epage>925</epage><pages>918-925</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><abstract>OBJECTIVES:Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects of mesenchymal stem/stromal cell treatment, as no previous study has conducted a comprehensive analysis of circulating cytokine levels in critically ill patients treated with mesenchymal stem/stromal cells.
DESIGN:Phase 1 dose-escalation trial.
PATIENTS:The interventional cohort (n = 9) of septic shock patients received a single dose of 0.3, 1.0, or 3.0 million mesenchymal stem/stromal cells/kg body weight (n = 3 per dose). The observational cohort received no mesenchymal stem/stromal cells (n = 21).
INTERVENTIONS:Allogeneic bone marrow-derived mesenchymal stem/stromal cells.
MEASUREMENTS AND MAIN RESULTS:Serial plasma samples were collected at study baseline prior to mesenchymal stem/stromal cell infusion (0 hr), 1 hour, 4 hours, 12 hours, 24 hours, and 72 hours after mesenchymal stem/stromal cell infusion/trial enrollment. Forty-nine analytes comprised mostly of cytokines along with several biomarkers were measured. We detected no significant elevations in a broad range of pro-inflammatory cytokines and biomarkers between the interventional and observational cohorts. Stratification of the interventional cohort by mesenchymal stem/stromal cell dose further revealed patient-specific and dose-dependent perturbations in cytokines, including an early but transient dampening of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mesenchymal stem/stromal cell treatment may alter innate immune responses and underlying sepsis biology.
CONCLUSIONS:A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials.</abstract><cop>United States</cop><pub>The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc</pub><pmid>30720538</pmid><doi>10.1097/CCM.0000000000003657</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-3493 |
| ispartof | Critical care medicine, 2019-07, Vol.47 (7), p.918-925 |
| issn | 0090-3493 1530-0293 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6629173 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Adult Biomarkers Clinical Investigations Cytokines - biosynthesis Dose-Response Relationship, Drug Female Humans Inflammation Mediators - metabolism Male Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cell Transplantation - methods Middle Aged Severity of Illness Index Shock, Septic - metabolism Shock, Septic - therapy |
| title | Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A54%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Mesenchymal%20Stem%20Cell%20Treatment%20on%20Systemic%20Cytokine%20Levels%20in%20a%20Phase%201%20Dose%20Escalation%20Safety%20Trial%20of%20Septic%20Shock%20Patients&rft.jtitle=Critical%20care%20medicine&rft.au=Schlosser,%20Kenny&rft.aucorp=Canadian%20Critical%20Care%20Trials%20Group%20and%20the%20Canadian%20Critical%20Care%20Translational%20Biology%20Group&rft.date=2019-07&rft.volume=47&rft.issue=7&rft.spage=918&rft.epage=925&rft.pages=918-925&rft.issn=0090-3493&rft.eissn=1530-0293&rft_id=info:doi/10.1097/CCM.0000000000003657&rft_dat=%3Cproquest_pubme%3E2179536814%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179536814&rft_id=info:pmid/30720538&rfr_iscdi=true |